Last C$0.17 CAD
Change Today 0.00 / 0.00%
Volume 40.2K
CZO On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 3:59 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ceapro inc (CZO) Snapshot

Open
C$0.19
Previous Close
C$0.17
Day High
C$0.20
Day Low
C$0.17
52 Week High
07/11/14 - C$0.20
52 Week Low
11/1/13 - C$0.03
Market Cap
10.4M
Average Volume 10 Days
24.7K
EPS TTM
--
Shares Outstanding
61.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEAPRO INC (CZO)

Related News

No related news articles were found.

ceapro inc (CZO) Related Businessweek News

No Related Businessweek News Found

ceapro inc (CZO) Details

Ceapro Inc., a biotechnology company, engages in the development and commercialization of health and wellness products and technology relating to plant extracts primarily in the United States, Germany, and Canada. The company markets natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; and veterinary therapeutic products comprising an oat shampoo, an ear cleanser, and a dermal complex/conditioner for veterinarians in Japan and Asia. Its products and technologies under research and development, or pre-commercial stage include CeaProve, a diabetes test meal to screen pre-diabetes and to confirm diabetes diagnosis; a drug delivery platform using its beta glucan technology delivers compounds for uses ranging from wound care and therapy to skin care treatments that reduce the signs of aging; an extension to the active ingredients product range; and various novel manufacturing technologies. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.

Founded in 1997

ceapro inc (CZO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$252.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: C$147.0K
Compensation as of Fiscal Year 2013.

ceapro inc (CZO) Key Developments

Ceapro Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014; Provides Volume Guidance for the Year of 2014

Ceapro Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of $1,954,347 against $2,012,279 a year ago. Income from operations was $319,989 against $402,811 a year ago. Net income for the year was $177,429 or $0.00 per diluted share against $408,171 or $0.01 per diluted share a year ago. The company expect to fulfill the forecasted increased demand for 2014, especially for flagship product, avenanthramides.

Ceapro Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014

Ceapro Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014 . Venue: Philadelphia, Pennsylvania, United States.

Ceapro Inc. Announces Consolidated Financial Results for the Year Ended December 31, 2013

Ceapro Inc. announced consolidated financial results for the year ended December 31, 2013. For the year, the company reported revenue of $6,524,062 against $5,165,276 a year ago. Income from operations was $447,027 against loss from operations of $514,546 a year ago. Net income for the year was $175,808 or $0.00 per diluted share against net loss for the year of $538,353 or $0.01 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CZO:CN C$0.17 CAD 0.00

CZO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CZO.
View Industry Companies
 

Industry Analysis

CZO

Industry Average

Valuation CZO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 22.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEAPRO INC, please visit www.ceapro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.